Who is sponsoring NCT01287728?

NCT01287728 is sponsored by Assistance Publique Hopitaux De Marseille.

What condition does NCT01287728 study?

NCT01287728 studies Abnormal Vaginal Flora.

What drugs are being tested in NCT01287728?

Interventions: Treatment BY METROMIDAZOLE.

What is the status of NCT01287728?

NCT01287728 is currently COMPLETED.

Last reviewed 2017-01-12 · How we verify

The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy

NCT01287728 Phase 3 COMPLETED

Abnormal vaginal flora is currently diagnosed among women (20-40%). It is associated with symptoms (bad smell, vaginal discharge) and adverse out-comes in pregnant and not pregnant women. The high recurrence rate raises the long-term effectiveness of therapy. The hypothesis is the persistence of bacteria associated with vaginal flora imbalance as Atopobium vaginae and Gardnerella vaginalis. At the present time there is a lack of an accurate marker for the risk of recurrence.

Details

Lead sponsor	Assistance Publique Hopitaux De Marseille
Phase	Phase 3
Status	COMPLETED
Enrolment	182
Start date	2011-01
Completion	2016-01

Conditions

Abnormal Vaginal Flora

Interventions

Treatment BY METROMIDAZOLE

Primary outcomes

To access the value of A. vaginae and G. vaginalis loads in predicting recurrence of abnormal vaginal flora over the course of 12 months after oral metronidazole therapy. — 2 YEARS

Countries

France